Expression of circANKRD36 as A New Biomarker in Diabetic Nephropathy Patients with type 2 Diabetes Mellitus
Abd-El Hafeez, H., Abd El-Hameed, Z., Mammdoh, Y., Kobeisy, M., Mohamed, M., Mohareb, D. (2025). Expression of circANKRD36 as A New Biomarker in Diabetic Nephropathy Patients with type 2 Diabetes Mellitus. EKB Journal Management System, 34(4), -. doi: 10.21608/ejmm.2025.390214.1686
Heba A. Abd-El Hafeez; Zeinab A. Abd El-Hameed; Yousra M. Mammdoh; Mohammad A. Kobeisy; Marwa M.H. Mohamed; Dina A. Mohareb. "Expression of circANKRD36 as A New Biomarker in Diabetic Nephropathy Patients with type 2 Diabetes Mellitus". EKB Journal Management System, 34, 4, 2025, -. doi: 10.21608/ejmm.2025.390214.1686
Abd-El Hafeez, H., Abd El-Hameed, Z., Mammdoh, Y., Kobeisy, M., Mohamed, M., Mohareb, D. (2025). 'Expression of circANKRD36 as A New Biomarker in Diabetic Nephropathy Patients with type 2 Diabetes Mellitus', EKB Journal Management System, 34(4), pp. -. doi: 10.21608/ejmm.2025.390214.1686
Abd-El Hafeez, H., Abd El-Hameed, Z., Mammdoh, Y., Kobeisy, M., Mohamed, M., Mohareb, D. Expression of circANKRD36 as A New Biomarker in Diabetic Nephropathy Patients with type 2 Diabetes Mellitus. EKB Journal Management System, 2025; 34(4): -. doi: 10.21608/ejmm.2025.390214.1686

Expression of circANKRD36 as A New Biomarker in Diabetic Nephropathy Patients with type 2 Diabetes Mellitus

Egyptian Journal of Medical Microbiology
Volume 34, Issue 4, October 2025
Document Type: New and original researches in the field of Microbiology.
DOI: 10.21608/ejmm.2025.390214.1686
Authors
Heba A. Abd-El Hafeez1; Zeinab A. Abd El-Hameed1; Yousra M. Mammdoh1; Mohammad A. Kobeisy2; Marwa M.H. Mohamed* 1; Dina A. Mohareb1
1Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assuit, Egypt
2Department of Internal Medicine, Faculty of medicine, Assiut University, Assuit, Egypt
Abstract
Background: Type 2 diabetes mellitus (T2DM) is a long-term metabolic disease defined by reduced pancreatic β-cell function and impaired insulin action in peripheral tissues, which cause sustained irregularities in glucose homeostasis, mild inflammation. Objectives: Recent study aimed to detect levels of circANKRD36 in white blood cells of T2DM patients and examine their relationship with pro- inflammatory mediators (TNF-α and IL-6) in DN patients withT2DM and to evaluate the role of circANKRD36 in the initiation and development of DN. Methodology: Blood samples obtained from people with diabetes mellitus type 2 (69) cases and Control participants (23). Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was applied to evaluate levels of CircANKRD36. Levels of pro-inflammatory cytokines such as interleukin IL-6 via chemiluminescence and tumor necrosis factor (TNF)-α was determined via enzyme-linked immunosorbent assay (ELISA). Results: CircANKRD36 showed high expression levels in patients with T2DM and DN, contribute to the development of DN and it was superior to inflammatory markers in detection of early stages of DN. Conclusion: CircANKRD36 levels were markedly up-regulated in T2DM patients in comparison to control group (P=< 0.001).
Keywords
Diabetes Mellitus type 2; Diabetic nephropathy; tumor necrotic factor-alpha; interleukin-6 and Circular ankyrin repeat domain 36
Statistics
Article View: 77